About 20 million people across the US, UK, and EU are taking GLP-1 receptor agonists like tirzepatide and semaglutide (Ozempic or Mounjaro are common brands) for weight loss and type 2 diabetes. As their use has surged, we’re learning more about their side-effects. One that’s been getting a lot of attention from researchers lately: hair loss.
In one survey of people who take these medications, 20% of respondents experienced hair shedding, although the lack of high-quality data from a randomized, controlled trial to assess this side-effect makes it difficult to know exactly how common it is.
